

October 8, 2013

Editorial Office
The World Journal of Hepatology

Dear

Enclosed is our manuscript entitled “HBV reactivation with rituximab-containing regimen,” which we revised based on reviewer comments and advice.

Editor:

1. We address the reviewer comments below on a point-by-point basis.
2. We revised the title for clarification.

Reviewer 1

1. We changed “proliferate” to “replicate” according to your suggestion.
2. We respectfully revised the page 3 line 6 according to our suggestion.
3. We deleted “while it is generally believed” from our text.
4. We revised page 6, line from the bottom, according to your suggestion.
5. We unified titer, titer level, and level to titer.
6. We changed (“?”) to “immunereconstitution” in our text.

Reviewer 2

1. We revised the title for clarification.
2. We revised our abstract according to your suggestion.
3. We changed “CTL” to “cytotoxic T cell” in the text.
4. We added the chemotherapy regimens to our text to clarify the THP.
5. We added the nucleoside analog dosages to our text.
6. We improved the figure legends.
7. We added table legends to our text.

8. We added a summary of recommendations according to your suggestions.

Reviewer 3

This report, which is a comprehensive review of HBV reactivation in rituximab treatment, was checked by a native-speaking rewriter.

We would like to thank the editor and reviewers for providing constructive criticism that considerably improved the clarity of our paper.

Sincerely,

Yutaka Tsutsumi, M.D.,
Department of Hematology, Hakodate Municipal Hospital
1-10-1, Minato-Cho, Hakodate 041-8680, Japan
Tel:+81-138-43-2000, Fax:+81-138-43-4426
e-mail:yutsutsu@shore.ocn.ne.jp